Current screening for prostate cancer uses a test called PSA. The PSA test measures the amount of prostate-specific antigen (PSA) in your blood. PSA is a protein produced by cancerous, noncancerous and inflamed prostate tissue. Therefore, determining what a high PSA score means can be complicated.
Because the PSA test measures an antigen produced by different types of cells, both cancerous and noncancerous, its value as a screening test has been the subject of much debate. There is no clear answer, which places physicians and their patients in an awkward position.
Testing done in the lab on men's prostate glands that have been removed, have shown our test to be very accurate, with both a very high sensitivity and specificity. These non-clinical trials have shown that the test can differentiate an enlarged benign prostate (BPH) from a cancerous or precancerous prostate in the lab. The question is whether we will achieve the same outstanding results in clinical trials with men that have not had their prostate gland removed.
We are optimistic because clinical trials for the colon, breast and lungs have all had outstanding results.
It should be noted that because only lab trials have been completed up to this point, and no clinical trials conducted, men understand that when using this test for prostate screening, that it will be for research purposes only.